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receiving ESPs was calculated by chemotherapy cycle, Hb level
during each cycle, and year. RESULTS: A total of 13,069 cancer
patients were studied. Median age was 61 years, 60% were
female, 38% had ECOG PS 0–2, and 30% had metastases.
Forty-four percent had solid malignant tumors of which breast,
lung and colorectal cancer were most common. Lymphoma was
the most common hematologic cancer. The percentages of
patients receiving ESPs during the initial cycle of the ﬁrst planned
chemotherapy regimen were 46.1%, 48.9%, and 48.2% at Hb
°Ü 10 g/dL; 44.5%, 52.7%, and 51.4% at Hb level of >10 to
<11 g/dL, in years 2004, 2005, and the ﬁrst 10 months of 2006
respectively. Across all years, the proportion of patients receiv-
ing ESPs at Hb < 11 g/dL was 49.1%. Few patients (2.6–4.1%)
with Hb °Y´ 12 g/dL received ESPs. CONCLUSION: ESP use
changed little over time. The overall proportion was under 50%
in patients with Hb < 11 g/dL, the guideline-recommended range
for ESP initiation. Further research is needed to understand the
reasons for apparent under-utilization of ESPs in community
oncology practices.
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OBJECTIVES: Establishment of a common unit for measuring
health can be helpful for health policy decision. The objective of
this study is to develop a common method and health unit for
comparative assessment for health outcome. METHODS: By
adjusting survival function with the mean of quality of life at
every time point ti and then summing up throughout lifetime, we
come up with a quality-adjusted life expectancy (QALE), which
has a common unit of quality-adjusted life year (QALY). QALE
= ∫ E(qol(ti/Xi))S(ti/Xi)dt where E(qol(ti/Xi)) is the expected
value of quality of life function at time ti and S(ti/Xi) is the sur-
vival function at time ti. Our approach is empirically imple-
mented on estimating potential impacts of following health
issues: the enforcement of helmet law in Taipei city and the con-
tamination of underground water by chlorinated hydrocarbons
from an electronics factory. RESULTS: The results showed that
there would be 1300 cases with head injury annually prevented
in Taipei city, which amounted to 6240 QALY saved. A case of
hepatocellular carcinoma was estimated to lose 19.5 QALY.
While the estimated likelihood from pollution of vinyl chloride,
trichloroethylene, and tetrachloroethylene in the ground water
were 8.4 × 10(−6), 1.4 × 10(−4), and 1.9 × 10(−4) based on
cancer slopes. Assuming that the population at risk in the
exposed community were about 1000 people, then the estimated
potential health impact would be a loss of 2, 32, and 44 QALM
(quality-adjusted life month), accordingly. We further extend the
method to psychometry and a unit of score-time and conduct
outcome evaluation for the effect of bone marrow transplanta-
tion after chemotherapy for acute myelogenous leukemia. CON-
CLUSION: We conclude that the method is feasible for
comparative health risk/outcome assessment for public health
and clinical policy decisions.
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OBJECTIVES: To estimate the cost-utility of two major strate-
gies for treating ALL in childhood, for informing decisions in 
the publicly-funded health care system of Ontario Canada.
METHODS: Most children diagnosed in Ontario with ALL are
treated according to Berlin-Frankfurt-Munster (BFM) or Dana-
Farber Cancer Institute (DFCI) protocols. The total cost of
health care resource utilization from diagnosis through end of
treatment will be based on mean total RIWs per patient treated
at two tertiary care centers in Ontario: one using BFM and the
other using DFCI. RIW data will be obtained from existing
administrative datasets. Cost per RIW will be standardized
across centers. Quality-adjusted life years (QALYs) will be based
on HUI health status surveys of patients, during (n > 300) 4 or
5 therapy phases (n > 316) and after therapy (n > 468).
RESULTS: This is the ﬁrst cost-utility study combining costs
based on RIWs, and QALYs from HUI measurements. RIWs
were developed, and are routinely used, for the funding and
administration of hospitals in Ontario. The HUI is a practical
tool for measuring the utility of overall health status, and has
been validated in many ALL studies. HUI surveys of numerous
patients will provide precise estimates of mean utility for QALYs.
No other study has surveyed these types of patients across treat-
ment phases. CONCLUSION: This is a useful approach that
bases costs and QALYs on valid, prospective measurements.
Validity of the RIW costing measurement system is well recog-
nized by administrators and health care policy analysts. Major
institutions, including Statistics Canada that has included the
HUI in every major population health survey since 1990, have
recognized the validity of HUI. The recognized validity of RIW
and HUI measures is expected to make the results appealing to
decision-makers.
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OBJECTIVES: Although the number needed to treat to prevent
a case of disease is a commonly used metric, the number needed
to vaccinate (NNV) is relatively new. We determined how adding
a quadrivalent human papillomavirus (6/11/16/18) vaccine to
screening in the U.S. would reduce the burden of HPV related-
disease using the NNV. METHODS: A Markov model of the
natural history of HPV infection incorporating screening and
vaccination was developed. A vaccine that prevents 100% of
HPV 6, 11, 16 and 18-associated disease, with a lifetime dura-
tion and 70% coverage, in conjunction with current screening
was compared to screening only. The NNV was calculated based
on the difference in the risk of genital warts, cervical pre-cancer
(deﬁned as cervical intraepithelial neoplasia 1, 2, or 3) or cancer
achieved with vaccination and screening compared to screening
only for a cohort of girls aged 12 years. We also estimated the
NNV for cohorts aged 13 to 26 years to account for recent
Centers for Disease Control Advisory Committee on Immuniza-
tion Practices (ACIP) recommendations. RESULTS: The NNV
